Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- (-) Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 87 Results
NPC @ DIA 2017 Annual Meeting: Exploring Comparative Effectiveness Research
NPC Chief Science Officer and Executive Vice President Robert Dubois, MD, PhD, will address how comparative effectiveness research is being used by health care decision-makers at the Drug Information…
How Are Health Plans Using Patient Data to Improve Outcomes?
Health plans collect enormous amounts of data through electronic health records, administrative claims, mobile health devices and other sources. Is the data simply sitting on a shelf, or is it being…
NPC Submits Comments to FDA on Exchange of Clinical and Economic Information
To achieve our shared goal of a high-performing, value-based health care system, informed and evidence-based decisions are needed. Greater efficiency and better care requires more information…
FDA Releases Guidance Documents on Communicating Clinical and Economic Information
The Food and Drug Administration (FDA) this week has released a series of draft guidance documents that clarify how and when different types of clinical and economic information may be communicated.
Pre-Approval Information Exchange Can Help Improve Population Health Decision-Making
Health care stakeholders, including NPC, gathered in September for a meeting hosted by the Academy of Managed Care Pharmacy to discuss potential ways to improve the exchange of information between…
NPC’s Dr. Jennifer Graff Testifies Before FDA on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Devices
NPC Vice President for Comparative Effectiveness Research Jennifer Graff, PharmD, highlighted two key issues in her testimony at the Food and Drug Administration public hearing on manufacturer…
Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges
This study provides an early evaluation of the CER Collaborative's training program's impact on learners’ self-reported abilities to evaluate and incorporate comparative effectiveness research…
2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the environment for health care decision-making found that stakeholders continue to have a high…
Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue
A study published in the September 2015 issue of The American Journal of Managed Care introduces a framework developed by the National Pharmaceutical Council (NPC) and AcademyHealth that could help…
Translating Comparative Effectiveness Research into Medicaid Payment Policy: Views from Medical and Pharmacy Directors
NPC supported a survey of Medicaid medical and pharmacy directors to better understand how policy makers in the state Medicaid programs view comparative effectiveness research (CER) and how they use…
2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
NPC's fifth annual survey, "Comparative Effectiveness Research and the Environment for Health Care Decision-Making," provides a snapshot of stakeholders’ perceptions of the key players in the…
Fifth Annual Survey on CER & Health Care Decision-Making: What Can We Expect This Year?
Since 2011, NPC has surveyed health care stakeholders to gauge their opinions about comparative effectiveness research (CER) and its impact on health care decision-making, including the organizations…
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.
2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making
Through this annual survey, NPC has been able to track changes in which organizations are perceived as influential in areas such as prioritizing, funding, conducting and monitoring CER, as well as…
When Is Evidence Sufficient for Decision-Making?
It takes an average of 17 years for new data, or evidence, to become part of routine care, according to the Institute of Medicine. A new study outlines influential factors that impact how quickly new…
Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues
One of many issues connected with comparative effectiveness research is how the findings will be communicated, particularly if they pertain to prescription drugs and if the findings could be useful…
Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
In a special supplement to the May 2012 Journal of Managed Care Pharmacy, National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, takes a closer look at comparative…
The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)
The National Pharmaceutical Council conducted its second annual survey of key health care stakeholders. 95 percent of respondents said that CER was "somewhat" or "very important" to them or their…
Making Informed Decisions: Assessing the Strengths and Weaknesses of Study Designs and Analytic Methods for Comparative Effectiveness Research
The purpose of this document is to provide brief descriptions of both experimental and nonexperimental study designs and methods that may be used to address CER study questions.